Effects of genetic and pharmacological inhibition of TNF-α in the regulation of inflammation in macrophages

Concetta Crisafulli, Maria Galuppo, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

Abstract

Tumour necrosis factor-α (TNF-α) is an inflammatory cytokine produced by circulating monocytes and resident macrophages during acute inflammation and is responsible for a diverse range of signalling events within cells, leading to necrosis or apoptosis. The biologic activities of TNF are mediated by two receptors TNFR1 and TNFR2, although a lot of studies demonstrated that most of the biological activities of TNF-α are mediated through TNFR1. In the present study, we want to evaluate the role of TNF-α on regulation of in vitro models of inflammation. In particular we used peritoneal macrophages, from TNF-αR1 knock out and TNF-αR1 wild-type mice, stimulated with LPS 10 μg/ml and IFN-γ 100 U/ml. Our results showed that the deletion of TNF-αR1 gene significantly reduced the degree of (i) MAPK activation, (ii) IκB-α degradation, (iii) phosphorylation of Ser536 on the NF-κB subunit p65 and (iv) iNOS and COX-2 expression. In addition, to confirm the pivotal role of TNF-α on regulation of peritoneal macrophages inflammation, we have also investigated the protective effects of infliximab, a TNF-α chimeric mouse/human IgG1 antibody against TNF-α. As shown in the present study, the cell incubation with infliximab (0.1 μg/ml, 1 μg/ml and 10 μg/ml) significantly leads to a concentration-dependent inhibition of the inflammatory mediators above described. In conclusion, our study demonstrates that pharmacological and genetic inhibition of the TNF/TNFR1 binding reduce the degree of macrophages inflammation caused by LPS/IFN-γ stimulation.

Original languageEnglish
Pages (from-to)332-340
Number of pages9
JournalPharmacological Research
Volume60
Issue number4
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Tumor Necrosis Factor-alpha
Macrophages
Pharmacology
Inflammation
Receptors, Tumor Necrosis Factor, Type I
Peritoneal Macrophages
Receptors, Tumor Necrosis Factor, Type II
Monocytes
Necrosis
Immunoglobulin G
Phosphorylation
Apoptosis
Cytokines
Antibodies
Genes

Keywords

  • Infliximab
  • Peritoneal macrophages
  • TNF-α

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of genetic and pharmacological inhibition of TNF-α in the regulation of inflammation in macrophages. / Crisafulli, Concetta; Galuppo, Maria; Cuzzocrea, Salvatore.

In: Pharmacological Research, Vol. 60, No. 4, 10.2009, p. 332-340.

Research output: Contribution to journalArticle

Crisafulli, Concetta ; Galuppo, Maria ; Cuzzocrea, Salvatore. / Effects of genetic and pharmacological inhibition of TNF-α in the regulation of inflammation in macrophages. In: Pharmacological Research. 2009 ; Vol. 60, No. 4. pp. 332-340.
@article{6923a63d156d40a58137a4832c67281d,
title = "Effects of genetic and pharmacological inhibition of TNF-α in the regulation of inflammation in macrophages",
abstract = "Tumour necrosis factor-α (TNF-α) is an inflammatory cytokine produced by circulating monocytes and resident macrophages during acute inflammation and is responsible for a diverse range of signalling events within cells, leading to necrosis or apoptosis. The biologic activities of TNF are mediated by two receptors TNFR1 and TNFR2, although a lot of studies demonstrated that most of the biological activities of TNF-α are mediated through TNFR1. In the present study, we want to evaluate the role of TNF-α on regulation of in vitro models of inflammation. In particular we used peritoneal macrophages, from TNF-αR1 knock out and TNF-αR1 wild-type mice, stimulated with LPS 10 μg/ml and IFN-γ 100 U/ml. Our results showed that the deletion of TNF-αR1 gene significantly reduced the degree of (i) MAPK activation, (ii) IκB-α degradation, (iii) phosphorylation of Ser536 on the NF-κB subunit p65 and (iv) iNOS and COX-2 expression. In addition, to confirm the pivotal role of TNF-α on regulation of peritoneal macrophages inflammation, we have also investigated the protective effects of infliximab, a TNF-α chimeric mouse/human IgG1 antibody against TNF-α. As shown in the present study, the cell incubation with infliximab (0.1 μg/ml, 1 μg/ml and 10 μg/ml) significantly leads to a concentration-dependent inhibition of the inflammatory mediators above described. In conclusion, our study demonstrates that pharmacological and genetic inhibition of the TNF/TNFR1 binding reduce the degree of macrophages inflammation caused by LPS/IFN-γ stimulation.",
keywords = "Infliximab, Peritoneal macrophages, TNF-α",
author = "Concetta Crisafulli and Maria Galuppo and Salvatore Cuzzocrea",
year = "2009",
month = "10",
doi = "10.1016/j.phrs.2009.05.001",
language = "English",
volume = "60",
pages = "332--340",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "4",

}

TY - JOUR

T1 - Effects of genetic and pharmacological inhibition of TNF-α in the regulation of inflammation in macrophages

AU - Crisafulli, Concetta

AU - Galuppo, Maria

AU - Cuzzocrea, Salvatore

PY - 2009/10

Y1 - 2009/10

N2 - Tumour necrosis factor-α (TNF-α) is an inflammatory cytokine produced by circulating monocytes and resident macrophages during acute inflammation and is responsible for a diverse range of signalling events within cells, leading to necrosis or apoptosis. The biologic activities of TNF are mediated by two receptors TNFR1 and TNFR2, although a lot of studies demonstrated that most of the biological activities of TNF-α are mediated through TNFR1. In the present study, we want to evaluate the role of TNF-α on regulation of in vitro models of inflammation. In particular we used peritoneal macrophages, from TNF-αR1 knock out and TNF-αR1 wild-type mice, stimulated with LPS 10 μg/ml and IFN-γ 100 U/ml. Our results showed that the deletion of TNF-αR1 gene significantly reduced the degree of (i) MAPK activation, (ii) IκB-α degradation, (iii) phosphorylation of Ser536 on the NF-κB subunit p65 and (iv) iNOS and COX-2 expression. In addition, to confirm the pivotal role of TNF-α on regulation of peritoneal macrophages inflammation, we have also investigated the protective effects of infliximab, a TNF-α chimeric mouse/human IgG1 antibody against TNF-α. As shown in the present study, the cell incubation with infliximab (0.1 μg/ml, 1 μg/ml and 10 μg/ml) significantly leads to a concentration-dependent inhibition of the inflammatory mediators above described. In conclusion, our study demonstrates that pharmacological and genetic inhibition of the TNF/TNFR1 binding reduce the degree of macrophages inflammation caused by LPS/IFN-γ stimulation.

AB - Tumour necrosis factor-α (TNF-α) is an inflammatory cytokine produced by circulating monocytes and resident macrophages during acute inflammation and is responsible for a diverse range of signalling events within cells, leading to necrosis or apoptosis. The biologic activities of TNF are mediated by two receptors TNFR1 and TNFR2, although a lot of studies demonstrated that most of the biological activities of TNF-α are mediated through TNFR1. In the present study, we want to evaluate the role of TNF-α on regulation of in vitro models of inflammation. In particular we used peritoneal macrophages, from TNF-αR1 knock out and TNF-αR1 wild-type mice, stimulated with LPS 10 μg/ml and IFN-γ 100 U/ml. Our results showed that the deletion of TNF-αR1 gene significantly reduced the degree of (i) MAPK activation, (ii) IκB-α degradation, (iii) phosphorylation of Ser536 on the NF-κB subunit p65 and (iv) iNOS and COX-2 expression. In addition, to confirm the pivotal role of TNF-α on regulation of peritoneal macrophages inflammation, we have also investigated the protective effects of infliximab, a TNF-α chimeric mouse/human IgG1 antibody against TNF-α. As shown in the present study, the cell incubation with infliximab (0.1 μg/ml, 1 μg/ml and 10 μg/ml) significantly leads to a concentration-dependent inhibition of the inflammatory mediators above described. In conclusion, our study demonstrates that pharmacological and genetic inhibition of the TNF/TNFR1 binding reduce the degree of macrophages inflammation caused by LPS/IFN-γ stimulation.

KW - Infliximab

KW - Peritoneal macrophages

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=69249214112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249214112&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2009.05.001

DO - 10.1016/j.phrs.2009.05.001

M3 - Article

C2 - 19450684

AN - SCOPUS:69249214112

VL - 60

SP - 332

EP - 340

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -